EG110A

EG110A is a non-replicating herpes simplex virus type 1 (HSV-1) vector-based gene therapy designed to treat neurogenic detrusor overactivity (NDO) and overactive bladder (OAB), particularly in patients with spinal cord injury. The therapy works by selectively targeting and silencing key bladder sensory neurons responsible for muscle overactivity, while preserving motor neuron function and normal bladder contraction. EG110A achieves this through the expression of the botulinum toxin F light chain (BoNT/F-LC), driven by a human calcitonin gene-related protein promoter, which ensures selective transgene expression in C-fiber bladder afferents. This mechanism leads to cleavage of the VAMP2 protein essential for neurotransmission, providing long-term relief from symptoms without causing urinary retention or systemic side effects. Developed using EG 427’s proprietary HERMES vector platform, EG110A is currently being evaluated in a phase 1b/2a clinical trial for safety and efficacy in adults with neurogenic bladder due to spinal cord injury[1][4][5][6][7].